A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

  • Moore, Maggie (Primary Chief Investigator (PCI))
  • Singhal, Nimit (Chief Investigator (CI))
  • Chin, Venessa T. (Chief Investigator (CI))
  • Karikios, Deme (Chief Investigator (CI))
  • Houghton, Baerin (Chief Investigator (CI))
  • Chan, Matthew Ming Ki (Chief Investigator (CI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date29/10/19 → 31/12/23

Keywords

  • Medical oncology
  • Lung cancer
  • Clinical trial